Skip to main content
Join CMKC members for a complimentary virtual event on December 10, 11am ET: CM MythBusters: https://bit.ly/3YXJynA. This is a fantastic opportunity to connect, collaborate, and debunk common myths about continuous manufacturing!
18.222.163.134

A Continuous Process for Manufacturing Apremilast. Part II: Process Characterization to Establish a Parametric Control Strategy

By Griffin, Daniel J.; Avci, Nadide Hazal; Sarkar, Nandini; Fostinis, James D.; Klitzing, Nicholas; Murray, James I.; Wimalasinghe, Rasangi; Spada, Simone; Zeng, Alicia; Beaver, Matthew G.; Hsieh, Hsiao-Wu

Published on

Abstract

This is Part II of a series on the development and characterization of an integrated continuous manufacturing (CM) process developed for the penultimate step in the synthesis of the drug substance Apremilast (Otezla). Part I gives the development history and highlights the achieved process intensification. Here, we describe the process characterization (PC) undertaken. In doing so, we point out aspects of characterization that are unique to an integrated CM process and give our strategy for navigating PC in this scenario. Moreover, we provide data that support a robust control strategy which relies on parametric control only (i.e., no in-process controls) followed by batch release of the produced Apremilast drug substance intermediate. Such a control strategy is advantageous as it minimizes divert-to-waste loss and operational costs.

Journal

Organic Process Research & Development. 2024

DOI

10.1021/acs.oprd.3c00403

Type of publication

Peer-reviewed journal

Affiliations

  • Amgen, Inc.

Article Classification

Research article

Classification Areas

  • API

Tags